APA (7th ed.) Citation

P, B., S, P., A, I., D, C., Y, M., S, L., . . . M, P. (2025). Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. Molecular cancer therapeutics, 24(12), 1989. https://doi.org/10.1158/1535-7163.MCT-24-0704

Chicago Style (17th ed.) Citation

P, Bergsma, et al. "Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma." Molecular Cancer Therapeutics 24, no. 12 (2025): 1989. https://doi.org/10.1158/1535-7163.MCT-24-0704.

MLA (9th ed.) Citation

P, Bergsma, et al. "Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma." Molecular Cancer Therapeutics, vol. 24, no. 12, 2025, p. 1989, https://doi.org/10.1158/1535-7163.MCT-24-0704.